Hikma Pharmaceuticals PLC

LSE:HIK.L

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

🏥 Hospitals & Clinics

🛍 Specialty Retail

Location

United Kingdom

Market Cap

USD 6.32 B

Share Price

USD 27.79

Avg Daily Volume

596,501

Change (1 day)

1.29%

Change (1 year)

17.26%

Change (YTD)

11.45%

Hikma Pharmaceuticals PLC Revenue for the year ending December 31, 2024: USD 3.13 B

Hikma Pharmaceuticals PLC Revenue is USD 3.13 B for the year ending December 31, 2024, a 8.77% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Hikma Pharmaceuticals PLC Revenue for the year ending December 31, 2023 was USD 2.88 B, a 14.22% change year over year.
Hikma Pharmaceuticals PLC Revenue for the year ending December 31, 2022 was USD 2.52 B, a -1.41% change year over year.
Hikma Pharmaceuticals PLC Revenue for the year ending December 31, 2021 was USD 2.55 B, a 9.06% change year over year.
Hikma Pharmaceuticals PLC Revenue for the year ending December 31, 2020 was USD 2.34 B, a 6.07% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue	Revenue	Gross Profit	Operating Income

LSE: HIK.L

Hikma Pharmaceuticals PLC

CEO	Mr. Riad Ali Mishlawi
IPO Date	Nov. 1, 2005
Location	United Kingdom
Headquarters	1 New Burlington Place
Employees	9,500
Sector	🏥 Health Care
Industries Pharmaceuticals 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies 🏥 Hospitals & Clinics 🛍 Specialty Retail

Description

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.